Acro Biomedical Co., Ltd.

ACBM OTC SEC CIK 1622996
Follow Acro Biomedical Co., Ltd. Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$21.4K −37.2% vs same quarter last year
EPS, diluted $0.00
Operating cash flow −$10.5K +88.8% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
$0
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$20M−$10M$0$10MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$101.1K
FY24$0−$42.3K
FY23$0−$8.8M
FY22$658.5K−$15.9M
FY21$1.2M−$7.7M
FY20$688K−$117.5K
FY19$193.5K−$371.6K
FY18$8M$419.7K
FY17$510K−$2.2K
FY16-−$43.4K
FY15-−$47.5K
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−3000%−2000%−1000%0%1000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY24---
FY23---
FY2221.3%−2410%−2410.2%
FY2121.7%−642.5%−642.8%
FY2023.2%−19%−17.1%
FY196.2%−218.4%−192%
FY1810.4%6.4%5.2%
FY1710%−0.4%−0.4%
FY16---
FY15---
Net margin vs the sectorMedian of Consumer companies filing with the SEC
  • Acro Biomedical Co., Ltd.
  • Consumer median
−3000%−2000%−1000%0%1000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearAcro Biomedical Co., Ltd.Consumer median
FY25-2.3%
FY24-3.4%
FY23-2.7%
FY22−2410.2%3.8%
FY21−642.8%2.9%
FY20−17.1%1.9%
FY19−192%2.6%
FY185.2%3%
FY17−0.4%2.6%
FY16-3.2%
FY15-3.4%

News

No stories filed under Acro Biomedical Co., Ltd. yet - coverage appears here as the news feed clusters it.